All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The levels of many biological molecules vary according to a biological rhythm, *i*.*e*., a cyclic change that roughly follows a 24-hour period. The periodicity is endogenously generated (circadian rhythms) but typically instructed (probably through dynamic epigenetic changes \[[@pone.0160577.ref001]\]) by the day/night light cycle (the diurnal-nocturnal cycle). Apart from being of considerable basic interest in physiology and disease, awareness of such biomolecular oscillations is of obvious importance for measurements in laboratory medicine and for studies developing *e*.*g*. diagnostic biomarkers. In humans, the principal circadian oscillator is found in the suprachiasmatic nucleus (SCN) of the hypothalamus. Several peripheral local clocks supplement it and together they coordinate the physiological cycles \[[@pone.0160577.ref002];[@pone.0160577.ref003]\]. Most circadian gene expression is organ specific and in the mouse genome up to half of all genes oscillate according to a circadian rhythm somewhere in the organism \[[@pone.0160577.ref004]\]. In the pineal gland which is controlled by the SCN almost 60% of 4,459 genes exhibit significant day/night expression changes \[[@pone.0160577.ref005]\]. Proper functioning of the clock system requires an intricate interplay between transcriptional, post-transcriptional, and post-translational mechanisms \[[@pone.0160577.ref006]\]. Recently, several studies have shown that circadian oscillations of protein expression (involving phases, periods, and amplitudes) to a much larger extent than previously envisioned are controlled post-transcriptionally \[[@pone.0160577.ref007];[@pone.0160577.ref008]\]. As an example, in the murine hepatic proteome about 20--50% of the transcripts representing 5--10% of total protein were not cyclic despite cyclic protein levels \[[@pone.0160577.ref009]--[@pone.0160577.ref011]\]. Also, next-generation sequencing studies indicate that 80% of clock-controlled genes are not rhythmically transcribed \[[@pone.0160577.ref012]\]. Post-transcriptional circadian regulation could, among other factors, be due to micro-RNA (miRNA) \[[@pone.0160577.ref013]--[@pone.0160577.ref016]\], and in one example involving miRNAs interacting with clock genes *Bmal1* and *Clock* in mice, miR-219 and miR-132 were demonstrated to be clock gene and light-regulated, respectively \[[@pone.0160577.ref017]\]. Also, circulating miRNAs in mice interacting with *Bmal1* were shown to be rhythmically fluctuating suggesting that they act as extracellular signals regulating peripheral circadian oscillators \[[@pone.0160577.ref018]\]. In addition, other noncoding RNAs are rhythmic in specific tissues \[[@pone.0160577.ref019]\], and because a single miRNA has many potential mRNA targets, one fluctuating miRNA may orchestrate fluctuations of many different proteins simultaneously. However, while several miRNAs and indeed the pre-miRNA processing machinery (Dicer RNase) are rhythmic in specific tissues such as the SCN, the eyes, and liver \[[@pone.0160577.ref008];[@pone.0160577.ref020]\] and may have circadian functions \[[@pone.0160577.ref021]\], it is not known if any of the circulating miRNA in human blood exhibits diurnal variation. It is also not known if any oscillating circulating, cell-free miRNA would function as a regulator of peripheral circadian oscillators and/or simply is a reflection of changing miRNA levels at the sites of central and peripheral oscillators. Yet another possibility is that some miRNA oscillations may occur because the miRNAs are transcribed together with oscillating protein-coding RNA. In any event, no studies of the physiological rhythmicity of extracellular miRNAs in the human circulation have been presented. This is important also because the circulating pool of miRNA is under scrutiny as a convenient reservoir of information on disease and functions in numerous conditions and diseases. Here, we study a panel of 92 miRNAs in plasma from healthy individuals. The miRNA panel includes miRNAs that are expressed in the pineal gland or have been reported as rhythmically expressed or as implicated in regulating oscillatory regulation of pineal gland/retinal gene expression in animal studies \[[@pone.0160577.ref006];[@pone.0160577.ref008];[@pone.0160577.ref017];[@pone.0160577.ref022]--[@pone.0160577.ref027]\] or have been predicted from literature and bioinformatics screening and shown in experiments with cellular miRNA to fluctuate \[[@pone.0160577.ref028];[@pone.0160577.ref029]\]. Also, we include miRNAs that are known to be detectable in plasma or are abundant in the central nervous system \[[@pone.0160577.ref030];[@pone.0160577.ref031]\]. This panel of miRNAs is here quantitatively determined in plasma samples obtained from a group of 24 healthy young men at regular 3-hr intervals in a controlled environment during 24 hours. Of the 79 miRNA that could be reliably measured we find n = 26 that are significantly rhythmic and which represent two main phase patterns. This is the first report of diurnal variations of circulating, extracellular human miRNAs. The findings add another important intra-individual variable to consider in the design and interpretation of biomarker development studies and suggest that investigations of functional roles of these miRNAs in the regulation of biological clocks are warranted.

Materials and Methods {#sec002}
=====================

Study design {#sec003}
------------

In the present study, samples from the Bispebjerg study of diurnal variations \[[@pone.0160577.ref032]\] were used to analyze variations of circulating cell-free micro RNA. In brief, 24 healthy Caucasian male volunteers (mean age 26 years) stayed for 24 hours at the hospital ward with 15 hours of wakefulness in ordinary day/room light (mean light intensity 219 lux) and 9 hours of sleep from 23:00 h to 08:00 h in the dark. Every third hour (nine time points in total), each participant had blood samples taken; sampling during the night was guided by red light (19 lux). During the awake period, the participants were allowed to carry out low intensity activities and standardized normal calorie meals were served at 09:30 h, 13:00 h and 19:00 h. The volunteers' regular routine of diurnal activity and nocturnal sleep were validated by the presence of a normal 24-hour melatonin pattern \[[@pone.0160577.ref032]\]. All participants signed an informed written consent before inclusion and the study was conducted according to the Helsinki declaration of 1975, as revised in 1983. The Regional Scientific Ethical Committee of the Capital Region of Denmark (protocol number H-B-2008-011) and the Danish Data Protection Agency (journal number 2008-41-1821) approved the study.

Analysis of circulating microRNA {#sec004}
--------------------------------

A total of 216 plasma samples representing the 9 time points from the 24 study subjects were included. Blood samples for analysis of miRNA were drawn in K~3~EDTA (ethylene diamine tetraacetic acid) plasma tubes (Greiner Bio-one, Frickenhausen, Germany). Immediately after sampling plasma was isolated by centrifugation at 1,500 *g* at 20°C for 10 minutes and stored at −80°C until analysis.

### RNA purification {#sec005}

A total RNA purification kit (Norgen Biotek Corp., Ontario, Canada) was used to purify RNA from 100 μL plasma according to the instructions of the manufacturer with small modifications: 10 mM dithiothreitol (DTT) (Sigma-Aldrich Co. LLC, Germany) and 1.7 pM synthetic *C*. *elegans* miR-54 and -238 (Tag Copenhagen A/S, Denmark) were added into lysis buffer. One uL of RNAse inhibitor (20 U/μL) (Applied Biosystems (ABI), Foster city, CA, USA) was added to every elution tube before elution of RNA. Purified RNA samples were kept at -20°C until used.

### Reverse transcription {#sec006}

Reverse transcription (RT) was performed by the TaqMan microRNA Reverse Transcription Kit (Applied Biosystems (ABI), Foster city, CA, USA) according to the instructions of the manufacturer with modifications: The RT-primer-mix consisted of equal volumes of each of 48 different 5x RT miR-specific stem-loop primers (Applied Biosystems (ABI), Foster city, CA, USA). Each reverse transcription reaction volume was 10 μL using 1 μL Multiscribe reverse transcriptase, 3 μl RT-primer-mix, 1 μL 10 X buffer, 0.2 μL 100 mM dNTPs, 0.15 μL RNase inhibitor and 4.65 μL RNA purified from plasma. Reverse transcription was performed on an ABI 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA) using a standard protocol (16°C, 30 min; 42°C, 30 min; 85°C 5 min; hold at 4°C). Reverse transcribed samples (cDNA) were kept at -20°C until used. The same procedure was used for a second set of miRNAs ([S1 Table](#pone.0160577.s006){ref-type="supplementary-material"}).

### Preamplification {#sec007}

For each of the 2 sets of analyses that were performed (*cf*. [S1 Table](#pone.0160577.s006){ref-type="supplementary-material"}) specific target amplification of the cDNA was accomplished using the TaqMan PreAmp master mix (Applied Biosystems (ABI), Foster city, CA, USA) with a mix of the TaqMan MicroRNA Assays (ABI) consisting of equal volumes of the 48 different 20x assays diluted with 1x TE buffer to a final concentration of 0.2x. Preamplification mixtures (10 μL) contained cDNA (diluted 1:3 with H~2~O) 2.5 μL, mixed with 5 μL 2x TaqMan PreAmp master mix and 2.5 μL of the 0.2x TaqMan miR-assay mix. Preamplification was performed on an ABI 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA) with the following program steps: 95°C for 10 min, 16 cycles of 95°C, 15 s and 60°C, 4 min, then hold at 4°C. Preamplified samples were kept at -20°C until used.

### Quantitative PCR {#sec008}

Preamplified samples (diluted 1:5 with H~2~O) and TaqMan 20x assays miRNAs were applied to primed 96.96 dynamic array chips using loading and assay reagents according to the manufacturer (Fluidigm Corp., USA). All miR-assays were performed in duplicate. The samples of this study were analyzed on three 96x96 chips (Fluidigm Corp., USA) with two different 48-miRNA assay panels (for a total of 6 chips). After loading the reaction chambers using the integrated fluid circuit (IFC) HX controller from Fluidigm, the real-time PCR including image capture after each cycle was performed in a BioMark real-time PCR system (Fluidigm Corp., USA) using single probe (FAM-MGB, reference: ROX) settings and GE 96x96 standard v1 protocol with 40 cycles. Data processing took place using the Fluidigm real-time PCR analysis software (v. 4.1.2).

### Data handling {#sec009}

The "auto detectors" setting was chosen for data from all of the chip runs. Data with average Cq values above 35 were excluded from data sets. Each remaining average Cq value was technically normalized with the average Cq of the spike-in synthetic miRNAs (cel-miR-54 and cel-miR-238) for that particular sample yielding the -ΔCq values (= average Cq of cel-miR-54 and cel-miR-238 − average Cq of the hsa-miR). This technical normalization is included to level out variations during the purification steps. These -ΔCq values were further normalized with the row-specific average ΔCq value of miRNAs that were detected in all samples to correct for variations in total input RNA. Thus, we used the average -ΔCq of 40 miRNAs in the first 48-miRNA panel and of 20 miRNAs in the second 48-miRNA panel ([S1 Table](#pone.0160577.s006){ref-type="supplementary-material"}) for each row to subtract from all miRNA-ΔCq values in each sample (row). These technically and row mean-normalized expression values were then used for the rhythmicity analysis. The normalized miRNA data are shown in [S2 Table](#pone.0160577.s007){ref-type="supplementary-material"}. Additionally, for the first miRNA panel (where miR-16 was included), we also normalized the data with row-specific miR-16 values instead of using row mean-normalization (data included in [S3 Table](#pone.0160577.s008){ref-type="supplementary-material"}).

Rhythmicity analysis {#sec010}
--------------------

As described earlier \[[@pone.0160577.ref032]\], under the assumption of 24-hour periods, the time-related miRNA expression data for the complete set of 216 results for each miRNA were fitted into a combined cosine and sine function and analyzed for possible diurnal rhythms. The methods for cosinor-rhythmometry for groups including the *p*-value calculation after linearization correspond to previously published methods \[[@pone.0160577.ref033]\]. The 24-hour rhythms were characterized by the rhythm parameters: mesor (rhythm-adjusted average about which oscillation occurs), amplitude (the difference between the peak (zenith) and lowest (nadir) value of the fitted cosinor curve) and time of peak and nadir \[[@pone.0160577.ref033]\]. Whether a parameter exhibited a clear diurnal rhythm was evaluated from the *p*-value and the shape of the cosine curve. The time-dependent distribution of the individual observations of the miRNAs presenting diurnal rhythms was graphically summarized as the best fitting cosine curve against time. At each time point, mean values and standard errors of the mean are shown. The data analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). A *p*-value \< 0.05 was considered significant. All data, including graphs of all detected miRNAs ([S1 Fig](#pone.0160577.s001){ref-type="supplementary-material"}) and the rhythmicity analysis data ([S1](#pone.0160577.s004){ref-type="supplementary-material"} and [S2](#pone.0160577.s005){ref-type="supplementary-material"} Files) are included as Supporting Information.

MiRNA target analysis {#sec011}
---------------------

Analysis of individual miRNA targets was based on miRTarBase 6.0 (<http://mirtarbase.mbc.nctu.edu.tw/>). The miRNAs were also investigated for targets in known central clock genes (*CRY1/2*, *PER1/2/3*) and in the MAPK pathway. For MAPK, all the genes in this pathway were identified through the KEGG homepage (in total 225 genes) and compared to all stringently validated genes (607 unique genes) regulated by the miRNAs found in the study (validated by 2 or more of the following methods: reporter assay, Western blot, or qPCR). Pathway representation of miRNA targets was accomplished using the KEGG pathway database (<http://www.genome.jp/kegg-bin/show_pathway?org_name=hsa&mapno=04010&mapscale=&show_description=hide>), target genes were marked in red, using the "User data mapping" function.

The miRNA targets were mapped to KEGG and Reactome pathways using the program gProfileR (v. 0.5.3) through R (v. 3.1.3). Organism was set to "hsapiens" and significant to "TRUE", otherwise default settings were used. The *p*-values obtained from gProfileR were used as values for heatmaps and all miRNA-pathway combinations that were not significant were assigned the value 0.05 for visualization. Heatmaps were made using the gplots package (vs. 2.17.0), trace was disabled, otherwise default settings were used.

Results and Discussion {#sec012}
======================

Diurnal fluctuations of plasma miRNAs in healthy volunteers {#sec013}
-----------------------------------------------------------

A normal 24-hour rhythm of the participants was confirmed by analyzing for melatonin that exhibited a clear rhythm (*p* \< 0.0001) with an amplitude (amp) of 19.84 pg/ml and a nightly peak level at 03:34 h in the study samples as previously reported \[[@pone.0160577.ref032]\].

We found 79 of the assayed 92 miRNAs to be reliably detected. Excluded miRNAs either gave no or weak (Cq \> 35) signal or only signals in a few (less than half) of the samples. To date there are no universally accepted circulating miRNAs that can be used as normalizing housekeeping genes and the concentration of the purified miRNA is too low to be determined UV spectrophotometry. Data were therefore normalized in two steps. First, normalization for technical variation was accomplished by using the values of spike-in synthetic non-mammalian miRNA. Second, normalization for variations in input total miRNA was accomplished by row mean-normalization \[[@pone.0160577.ref034]\] using the mean Cq value in each row (sample) of miRNAs expressed in all samples. Specifically, the row mean of 40 miRNAs in the first panel-experiment and of 20 miRNAs in the second panel-experiment were used for normalization.

Of the 79 detected miRNAs 26 were significantly (*p* \< 0.05) rhythmic (Figs [1](#pone.0160577.g001){ref-type="fig"} and [2](#pone.0160577.g002){ref-type="fig"}; in [S1 Fig](#pone.0160577.s001){ref-type="supplementary-material"} is included all the graphs of the 79 detected miRNAs). The time-of-day dependent distribution of the individual observations of the miRNAs presenting diurnal rhythms is listed in [Table 1](#pone.0160577.t001){ref-type="table"}. In the graphs the sleep periods are indicated in grey and miRNAs peaking at night (n = 12, [Fig 1](#pone.0160577.g001){ref-type="fig"}) and during day (n = 14, [Fig 2](#pone.0160577.g002){ref-type="fig"}) are shown in the respective figures.

![Nocturnal miRNAs.\
Sleep periods are indicated in grey. Individual points represent the mean and SEM of the values of the 24 test individuals.](pone.0160577.g001){#pone.0160577.g001}

![Diurnal miRNAs.\
Sleep periods are indicated in grey. Individual points represent the mean and SEM of the values of the 24 test individuals.](pone.0160577.g002){#pone.0160577.g002}
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###### Rhythmic, circulating miRNAs (*p* \< 0.05) ranked according to their peak time (Max time).

![](pone.0160577.t001){#pone.0160577.t001g}

  miRNA               Mesor   Amplitude   Max time   Min time   P-value
  ------------------- ------- ----------- ---------- ---------- --------------
  hsa-miR-375         -6.4    1.2         00:32      12:32      *\<0*.*0001*
  hsa-miR-150-5p      0.4     0.5         01:54      13:54      *0*.*001*
  hsa-miR-378a-3p     9.4     0.4         01:56      13:56      *0*.*02*
  hsa-miR-206         -4.0    0.6         01:59      13:59      *0*.*0009*
  hsa-miR-28-3p       1.5     0.7         02:17      14:17      *0*.*02*
  hsa-miR-708-5p      3.0     0.7         02:20      14:20      *0*.*02*
  hsa-miR-222-3p      2.0     0.6         02:38      14:38      *0*.*02*
  hsa-miR-383-5p      0.4     0.3         03:42      13:42      *0*.*02*
  hsa-miR-155-5p      9.2     0.5         04:25      16:25      *\<0*.*0001*
  hsa-miR-363-3p      2.7     0.6         04:33      16:33      *0*.*006*
  hsa-miR-483-5p      4.8     0.3         04:33      16:33      *0*.*0004*
  hsa-miR-208a-3p     8.0     0.6         06:29      18:29      *0*.*003*
  hsa-miR-27a-3p      -3.7    0.3         09:52      21:52      *0*.*02*
  hsa-miR-223-3p      3.4     0.3         11:38      23:38      *0*.*02*
  hsa-miR-24-3p       -0.3    0.4         12:23      00:23      *0*.*02*
  hsa-miR-19-3p       -1.4    0.3         13:04      01:04      *0*.*04*
  hsa-miR-140-5p      -2.3    0.4         14:19      02:19      *\<0*.*0001*
  hsa-miR-15b-5p      -3.3    0.4         14:41      02:41      *0*.*03*
  hsa-miR-103a-3p     -1.0    0.5         14:44      02:44      *0*.*03*
  hsa-miR-139-5p      -6.4    0.8         15:15      03:15      *0*.*0006*
  hsa-miR-199a/b-3p   1.3     0.4         16:06      04:06      *0*.*0003*
  hsa-miR-203-3p      -1.9    0.5         17:03      05:03      *0*.*002*
  hsa-miR-34a-5p      6.4     1.6         17:09      05:09      *0*.*02*
  hsa-miR-15a-5p      -1.4    1.3         17:31      05:31      *0*.*02*
  hsa-miR-106b-5p     -4.3    0.4         17:58      05:58      *0*.*006*
  hsa-miR-192-5p      -5.4    0.9         21:28      09:28      *0*.*0001*

As an alternative to row mean-normalization it might be possible to use single miRNAs as endogenous controls in the same way as small nucleolar RNAs are used in tissue and cell-miRNA profiling. In extensive method comparisons between serum and plasma, miR-16 emerged as one possible candidate for such an abundant, endogenous circulating miRNA normalizer \[[@pone.0160577.ref035]\]. Other studies, however, have not found miR-16 to be appropriate for this purpose. One reason is that it is associated with at least 10 non-neoplastic diseases \[[@pone.0160577.ref036]\] and is differently reported as a stable and a disease-associated circulating miRNA even in studies of the same disease \[[@pone.0160577.ref037]\]. Also, no studies have addressed the rhythmicity of miR-16 itself in the circulation. Here, we find it quite stable ([S2 Fig](#pone.0160577.s002){ref-type="supplementary-material"}) during the 24-hour period. The two normalization methods (cf. side-by-side comparison in [S3 Fig](#pone.0160577.s003){ref-type="supplementary-material"}) yield overall quite similar time-curves, but miR-16 normalization leads to less significant miRNAs found in the rhythmicity analysis, probably due to the more pronounced variation of the ΔCq-values at each time point. Thus, when miR-16 was used for normalization instead of row mean-normalization of the first miRNA panel data, a total of 9 miRNAs, all part of the miRNAs emerging as significantly rhythmic after row mean-normalization, were confirmed. However, 9 others were not found ([S1 Table](#pone.0160577.s006){ref-type="supplementary-material"}) and in view of this and of the lack of consensus regarding single-miRNA normalizers we decided to use the row mean-normalization method throughout.

We compared our findings with mammalian miRNAs bioinformatically predicted to target clock genes, their isoforms, and genes associated with a pattern of circadian protein expression despite constitutively expressed mRNA \[[@pone.0160577.ref028]\]. In the present study we included 17 of the 38 miRNAs equally predicted by three different miRNA-target prediction programs and with validated rhythmic target genes. Of these 17 miRNAs, 5 (miRs-9, -29b, -96, -219, and -346) were not reliably detected and 10 miRNAs did not exhibit diurnal oscillation while 2 (miRs-24 and -27a) did show a significant diurnal variation. Even though we do not find a significant diurnal variation of miR-27b (*p* = 0.08) our data show that the closely related miR-27a (one nucleotide difference) does exhibit rhythmicity (*p* = 0.02). In leukocytes miR-27b was previously shown to display rhythmicity in samples from two out of five normal subjects \[[@pone.0160577.ref028]\]. In another study of fluctuations of leukocyte miRNAs \[[@pone.0160577.ref029]\] miR-16 and miR-181a were shown to fluctuate in those 4 out of 6 subjects where the expression was highest at daytime. In our data, representing the mean of 24 healthy volunteers, we do not find a concurrent rhythmic variation of these two miRNAs. It is highly warranted in future studies to address the rhythmicity of the miRNA precursors (pri-miRs) in specific cell types, *e*.*g*. leukocytes to address if miRNA rhythmicity is directly transcriptionally regulated.

The human homologues of mouse miRNAs -219a and -132 which exhibit rhythmic expression in mouse brain tissue and act as clock-transcription factor and light-regulated miRNAs, respectively \[[@pone.0160577.ref017]\] were included in our study but miR-219a was found not to be detectable in plasma, and miR-132 had a stable, non-cyclic expression. Also, while we were able to detect miR-182 in plasma, it was not oscillating. Its pre-form has been reported to be modulating the circadian clock and was abnormally processed in a study of depressive patients with sleep disorders \[[@pone.0160577.ref024]\]. Regulation by other environmental factors such as *e*.*g*. food intake is possible, but fasting was previously found not to affect the levels of 162 circulating human miRNAs \[[@pone.0160577.ref038]\]. This study identified miR-99a-5p and miR-139-5p as novel endogenous controls for serum miRNA because of stable values across individuals. However, our data show that while the levels of miR-99a-5p are not rhythmic they are quite variable (with a difference of 21% between the highest and lowest mean values) during the 24-hour period. For miR-139-5p, the data in fact show clear rhythmicity (*p* = 0.0006). None of these two miRNAs therefore appears to be optimal as endogenous normalizers for plasma miRNAs.

Target analysis of rhythmic plasma miRNAs {#sec014}
-----------------------------------------

The presence of specific, circulating, cell-free miRNAs that display diurnal rhythmicity in plasma from healthy humans is a novel finding. The mechanisms behind the fluctuations are unknown. Thus, miRNA-rhythmicity may be due to oscillating transcription, fluctuating release from cells, fluctuating half-lives, and any combinations of these factors. The putative functional roles of circulating miRNA are unclear even though a number of studies show that protein expression may be affected by cell-free miRNA taken up by target cells \[[@pone.0160577.ref039];[@pone.0160577.ref040]\]. For that reason the potential targets of the specific rhythmic miRNAs may be of interest even though the miRNAs identified here are not envisioned to be functional as translational repressors while present in the circulation but only after being taken up by target cells or tissues. With the caveat that this is not experimentally addressed in the present study and that most of the miRNAs in the circulation may in fact reflect the end result of cellular disposal we analyzed for targets in the circadian system and also for common targets using bioinformatics approaches.

In the case of miR-375 --a highly significantly fluctuating miRNA (*p* \< 0.0001) there are a number of functionally validated targets of possible relevance including transcription factor *SP1* which is among the top 5 transcription factors associated with circadian clocks in mice \[[@pone.0160577.ref041]\]. *MECP2* (methyl CpG binding protein), a circadian-cycle dependent epigenetic regulator of gene expression in the brain \[[@pone.0160577.ref042]\] is also a validated target of miR-375. Another interesting target is *RASD1* which regulates responsiveness of the circadian clock and is rhythmically expressed in the SCN in mouse models \[[@pone.0160577.ref043]\]. Finally, miR-375 also targets *MYC* which competes with the *Clock-Bmal1* master circadian transcription factor for the same nucleotide sequence motifs in the genome \[[@pone.0160577.ref044]\]. The miR-483 (*p* = 0.0004) is a pineal miRNA and was shown in rats to target melatonin expression \[[@pone.0160577.ref022]\].

In mice, miR-155-5p (*p* \< 0.0001) targets the *Bmal1* mRNA directly and is an important regulator of the innate immune response that is conditioned across the circadian day in myeloid cells \[[@pone.0160577.ref045]\]. Human miR-155 is homologous to mouse miR-155 (only one nucleotide substitution) and therefore likely to be functionally similar. This proinflammatory miRNA is also found in lymphocytes and since lymphocyte counts display rhythmicity, *i*.*e*. a decline in the morning and a peak during night \[[@pone.0160577.ref002];[@pone.0160577.ref046];[@pone.0160577.ref047]\], the miR-155 fluctuations observed in plasma may, at least partly, reflect the physiologically variable lymphocyte counts. Both miR-155-5p and miR-206 (*p* = 0.0009) target *CCND1*, a cell cycle marker that is timed by clock proteins in the mouse \[[@pone.0160577.ref048]\]. Also, miR-155-5p targets the *CEBPB* transcription factor which controls practically all members of the core circadian clock system \[[@pone.0160577.ref049]\].

miR-208a-3p (*p* = 0.003) has *Sox-6* as one of its validated targets (as does miR-155-5p) and *Sox-6* expression is negatively correlated with *Per1* expression. *Per1* is a key circadian gene in the mouse involved in a negative feed-back loop with the *Clock* transcription factor \[[@pone.0160577.ref041]\]. Another miR-208a-3p target, *CDKN1A* (or p21), is a cyclin-dependent kinase inhibitor controlling G1 cell cycle progression and is circadian in a number of mouse tissues \[[@pone.0160577.ref041]\]. It is also a validated target of two other clearly rhythmic miRNAs in the present study, *i*.*e*., miR-363-3p (*p* = 0.006) and miR-106b-5p (*p* = 0.006). Finally, the transcription factor est-1, which is yet another functionally validated miR-208a target, regulates many circadian genes in the SCN and is down-regulated during the day and upregulated during the night in rats \[[@pone.0160577.ref050]\].

MiR-139-5p (*p* = 0.0006) targets *IGF1R* which together with *PDK1* (a kinase downstream of *IGF1R* (both *IGF1R* and *PDK1* are targeted by miR-375)) has been shown to be induced by light in a study of the coupling of cell proliferation with diurnal/circadian cycles in a human breast cancer model \[[@pone.0160577.ref051]\]. It also targets *ROCK2* that oscillates under the control of the *RORα* clock gene, and thus regulates differences in myosin light chain phosphorylation leading to rhythmicity in the contractility of the vascular system \[[@pone.0160577.ref052]\].

miR-106b-5p (*p* = 0.006) targets *CDKN1A* (p21) as mentioned above in addition to *PTEN* which appears to be involved in the maintenance of circadian rhythm in mouse models \[[@pone.0160577.ref053]\]. In addition, p21 is a target of p53 which is targeted by both miR-375 (*p* = 0.0001) and miR-150-5p (*p* = 0.001). In turn, p21 effects the phosphorylation of Rb1, another validated target of miR-106-5p, and thereby affects cell cycling.

Transcripts of a number of genes involved in epigenetic regulation (acetyltransferases, deacetylases, and DNA methyltransferases (DNMT1, HDAC4, HDAC7, KAT2B, MECP2)) are strongly validated targets of the highly significant rhythmic miRNAs found in the present study. Thus, miR-140-5p (*p* \< 0.0001) targets *HDAC4* as well as *HDAC7*, both histone class II deacetylases which regulate transcription and are well established circadian regulators \[[@pone.0160577.ref054]\]. Another epigenetic clock regulator, *DNMT1*, is also a miR-140-5p target \[[@pone.0160577.ref001]\]. Finally, a histone acetyltransferase, *KAT2B* which is a circadian transcriptional co-activator of activators of clock genes \[[@pone.0160577.ref055]\] is targeted by miR-106b-5p.

### Systems analysis of rhythmic circulating miRNAs and their targets {#sec015}

Analysis of core clock gene mRNA sequences reveal that the *CRY2* mRNA has two weakly interacting miRNAs among the 26 significantly fluctuating miRNAs found in this study, *i*.*e*., miR-106-5p and miR-24-3p while none targets *CRY1*. For the *Per* genes we find that *Per1* is a weakly predicted target for 2 of the fluctuating plasma miRNAs, miR-28-3p and miR-103a-3p, discovered in the present study while *Per2* is predicted to interact weakly with miR-24-3p and miR-363-3p. None of the fluctuating miRNAs are predicted to target *Per3*.

When including the target genes of the 29 miRNAs (for miRNAs 19-3p, 199-3p, and 203-3p we used a and b as separate miRNAs) in the pathway analyses, no compelling clustering is visualized except that cell cycling genes and fibroblast and epidermal growth factor receptor-associated intracellular kinase cascades are shared as targets of a number (\> 2) of the cyclic miRNAs ([Fig 3A](#pone.0160577.g003){ref-type="fig"}). Looking at genes of relevance for intracellular signaling we find that a total of 38 genes (*RAPGEF*, *RAP1B*, *FGF7*, *FGF9*, *EGFR*, *FGFR3*, *PDGFRA*, *PDGFRB*, *GRB2*, *HRAS*, *KRAS*, *MAP2K1*, *MAPK1*, *MAPK3*, *MYC*, *SRF*, *FOS*, *STMN1*, *TNF*, *TGFB1*, *TGFBR1*, *CASP3*, *TAB2*, *PAK2*, *MAP3K8*, *MAP2K4*, *CRKL*, *MAPK14*, *JUN*, *TP53*, *MEF2C*, *AKT1*, *AKT2*, *AKT3*, *HSPA1B*, *MAP3K14*, *CHUK*, *NFKB1*) are both among the strong evidence targets of the cyclic miRNAs as well as situated in the MAPK pathway. These genes are marked with red in [Fig 3B](#pone.0160577.g003){ref-type="fig"}.

![**A, Heatmap showing overrepresented Reactome pathways.** For each miRNA all strong targets (defined by miRTarBase) was used for GO analysis using gProfileR. Only miRNAs where target genes were significantly overrepresented in one or more pathways are shown. Colors indicate *p*-value with red colors being associated with lower *p*-values. Non-significant matches were all assigned the value 0.05. The color bar on top of the plot indicates groups belonging into 5 time-point specific expression groups (group 1: red, group 2: blue, group 3: green, group 4: black, group 5: pink). **B, MAPK pathway targets.** Strongly binding predicted MAPK pathway targets of significant rhythmic miRNAs of the present study are colored red.](pone.0160577.g003){#pone.0160577.g003}

Conclusions {#sec016}
===========

The present study identifies circulating miRNAs that undergo clear rhythmic fluctuations in abundance during a 24-hour period in a group of 24 healthy young male individuals. The findings are specific in the sense that only a third (26/79) of the detected miRNAs display rhythmicity and in the sense that two different main phase patterns are observed---one peaking during night and one pattern peaking during day. Despite the challenge of normalizing data of circulating miRNA abundance due to the lack of accepted "housekeeping" circulating miRNAs \[[@pone.0160577.ref034]\] these observations argue against variations in sampling and RNA purification conditions leading to the observed differences. Thus, this is, to our knowledge, the first time diurnal variations in the levels of human circulating, cell-free miRNAs have been reported. The present study is merely descriptive and does not give a basis for a unifying understanding of the roles of the individual circadian miRNAs especially because of the general target promiscuity of miRNAs and because of the uncertainties regarding the regulation of miRNA synthesis, release to the circulation, and regulation of circulating miRNA removal and degradation. Indeed, a recent report showed that only 7% (4/57) mature miRNAs originating from oscillating primary transcripts were rhythmically expressed \[[@pone.0160577.ref021]\]. Future work involves cellular and animal models with targeted miRNA disruption and induction. Also, a confirmative analysis over more than one diurnal cycle would be valuable.

In any event, the finding that some miRNAs vary according to a diurnal clock is important information for all studies that include analysis of the levels of circulating miRNAs and the findings also constitute a starting point for further studies of the importance of miRNA oscillations in physiology and disease.

Supporting Information {#sec017}
======================

###### Graphs of all detected miRNA ΔCq values (V1) as a function of time (hours after first sample at 09 am).

Individual points represent the mean and SEM of the values of the 24 individuals included in the study. In case of significant rhythmicity, the p-values are included on the graphs.

(PPTX)

###### 

Click here for additional data file.

###### Representations of miR-16 data.

Individual data points, mean and SEM are shown for row mean-normalized, technically normalized, and raw (not normalized) miR-16 data.

(PPTX)

###### 

Click here for additional data file.

###### Graphs of miRNAs detected in the first panel.

Comparison side-by-side of row mean-normalized with row miR-16 normalized data. Data points (mean and SEM) and curve fitting are shown.

(PPTX)

###### 

Click here for additional data file.

###### Rhytmicity analysis of detected miRNAs by cosinor-rhythmometry using row mean normalized data.

The p-values are indicated in red.

(DOCX)

###### 

Click here for additional data file.

###### Rhytmicity analysis of detected miRNAs by cosinor-rhythmometry using miR-16 normalized data.

The p-values are indicated in red.

(DOCX)

###### 

Click here for additional data file.

###### The two miRNA panels employed in this study.

Designations (assay name, ID and miRBase name) and sequences are included. Also indicated are excluded miRNAs based on no signal (red background) or too few data (light blue background). For the first panel where data were normalized using both miR-16 and row mean normalization the miRNA in red are those that were significantly rhythmic using the row mean normalized data only while those that are written in green are those that were significantly rhythmic using both normalization methods.

(XLSX)

###### 

Click here for additional data file.

###### Data file panel 1 and 2.

Row mean normalized data for both miRNA panels.

(XLSX)

###### 

Click here for additional data file.

###### Data file, panel 1.

miR-16 normalized data.

(XLSX)

###### 

Click here for additional data file.
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